Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer

Published:2013-06 Issue:3 Volume:129 Page:452-458
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Armstrong Deborah K.,White Allen J.,Weil Susan C.,Phillips Martin,Coleman Robert L.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference30 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?;Huang;Cancer,2008

3. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines;Miotti;J Cell Biochem,1997

4. A step further in understanding the biology of the folate receptor in ovarian carcinoma;Bagnoli;Gynecol Oncol,2003

5. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo;Bottero;Cancer Res,1993

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review;Frontiers in Pharmacology;2024-06-14

2. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer;Medicine;2024-05-17

3. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements;International Journal of Molecular Sciences;2024-02-03

4. Antibody-Drug Conjugates in Gynecologic Cancers;Current Treatment Options in Oncology;2024-01

5. Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11